Altargo (retapamulin)
- Region
- 🇪🇺 EU
- Active substance
- retapamulin
- Company
- Glaxo Group Ltd
- Status
- Withdrawn
- Therapeutic area
- Impetigo; Staphylococcal Skin Infections
- EU approval
- Thu 24 May 2007
- Application
- EMEA/H/C/000757
- ATC
- D06AX13
- Official record
- www.ema.europa.eu
Indication
Short term treatment of the following superficial skin infections: impetigo; infected small lacerations, abrasions or sutured wounds. See sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Follow Altargo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.